MCL1 and B-cell chronic lymphocytic leukemia: Indeed, multiple groups have demonstrated that a portion CLL patients with decreased sensitivity to venetoclax arise from a cellular dependence on MCL1, which can be overcome through inhibition of its expression [18, 19].